266 related articles for article (PubMed ID: 31388979)
21. Laboratory evaluation of the Anyplex™ II MTB/MDR and MTB/XDR tests based on multiplex real-time PCR and melting-temperature analysis to identify Mycobacterium tuberculosis and drug resistance.
Igarashi Y; Chikamatsu K; Aono A; Yi L; Yamada H; Takaki A; Mitarai S
Diagn Microbiol Infect Dis; 2017 Dec; 89(4):276-281. PubMed ID: 28974394
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.
Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J
Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426
[TBL] [Abstract][Full Text] [Related]
23. Redefining MDR-TB: Comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan.
Jou R; Lee WT; Kulagina EV; Weng JY; Isakova AI; Lin WH; Antonova OV; Wu MH; Arslanbaeva LR; Tasi HY; Nosova EY; Zimenkov DV
Infect Genet Evol; 2019 Aug; 72():141-146. PubMed ID: 30593924
[TBL] [Abstract][Full Text] [Related]
24. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
25. Genotypic diversity of multidrug-, quinolone- and extensively drug-resistant Mycobacterium tuberculosis isolates in Thailand.
Disratthakit A; Meada S; Prammananan T; Thaipisuttikul I; Doi N; Chaiprasert A
Infect Genet Evol; 2015 Jun; 32():432-9. PubMed ID: 25847698
[TBL] [Abstract][Full Text] [Related]
26. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
[TBL] [Abstract][Full Text] [Related]
27. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
Brouqui P; Quenard F; Drancourt M
Int J Antimicrob Agents; 2017 May; 49(5):554-557. PubMed ID: 28336312
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis.
Kashyap A; Singh PK; Silakari O
Drug Metab Rev; 2018 Nov; 50(4):448-465. PubMed ID: 30343607
[TBL] [Abstract][Full Text] [Related]
29. In Silico Drug Target Discovery Through Proteome Mining from M. tuberculosis: An Insight into Antivirulent Therapy.
Bhattacharya S; Ghosh P; Banerjee D; Banerjee A; Ray S
Comb Chem High Throughput Screen; 2020; 23(3):253-268. PubMed ID: 32072892
[TBL] [Abstract][Full Text] [Related]
30. Prevalence, associated factors, outcomes and transmission of extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in São Paulo, Brazil: a cross-sectional study.
Gallo JF; Pinhata JMW; Simonsen V; Galesi VMN; Ferrazoli L; Oliveira RS
Clin Microbiol Infect; 2018 Aug; 24(8):889-895. PubMed ID: 29175351
[TBL] [Abstract][Full Text] [Related]
31. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
32. Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use".
Amaral L; Molnar J
Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):109-14. PubMed ID: 20156179
[TBL] [Abstract][Full Text] [Related]
33. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
[TBL] [Abstract][Full Text] [Related]
34. A study on pre-XDR & XDR tuberculosis & their prevalent genotypes in clinical isolates of Mycobacterium tuberculosis in north India.
Singhal P; Dixit P; Singh P; Jaiswal I; Singh M; Jain A
Indian J Med Res; 2016 Mar; 143(3):341-7. PubMed ID: 27241648
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
[TBL] [Abstract][Full Text] [Related]
36. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated from south-central in China.
Yu XL; Wen ZL; Chen GZ; Li R; Ding BB; Yao YF; Li Y; Wu H; Guo XK; Wang HH; Zhang SL
J Antibiot (Tokyo); 2014 Apr; 67(4):291-7. PubMed ID: 24326341
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the genetic diversity of extensively-drug resistant Mycobacterium tuberculosis clinical isolates from pulmonary tuberculosis patients in Peru.
Cáceres O; Rastogi N; Bartra C; Couvin D; Galarza M; Asencios L; Mendoza-Ticona A
PLoS One; 2014; 9(12):e112789. PubMed ID: 25489950
[TBL] [Abstract][Full Text] [Related]
39. Effective therapy with the neuroleptic thioridazine as an adjunct to second line of defence drugs, and the potential that thioridazine offers for new patents that cover a variety of "new uses".
Amaral L; Viveiros M; Molnar J; Kristiansen JE
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):84-7. PubMed ID: 21548876
[TBL] [Abstract][Full Text] [Related]
40. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
Lee H; Suh JW
J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
